Aperio Group LLC boosted its holdings in Catalent Inc (NYSE:CTLT) by 7.0% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 33,563 shares of the company’s stock after purchasing an additional 2,185 shares during the quarter. Aperio Group LLC’s holdings in Catalent were worth $1,529,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Atria Investments LLC boosted its position in Catalent by 12.6% in the third quarter. Atria Investments LLC now owns 10,208 shares of the company’s stock worth $465,000 after purchasing an additional 1,144 shares during the last quarter. Oregon Public Employees Retirement Fund boosted its position in Catalent by 2.6% in the second quarter. Oregon Public Employees Retirement Fund now owns 51,962 shares of the company’s stock worth $2,177,000 after purchasing an additional 1,299 shares during the last quarter. State of Alaska Department of Revenue boosted its position in Catalent by 9.7% in the third quarter. State of Alaska Department of Revenue now owns 15,648 shares of the company’s stock worth $712,000 after purchasing an additional 1,378 shares during the last quarter. United Services Automobile Association boosted its position in Catalent by 6.4% in the second quarter. United Services Automobile Association now owns 23,725 shares of the company’s stock worth $994,000 after purchasing an additional 1,418 shares during the last quarter. Finally, Russell Investments Group Ltd. boosted its position in Catalent by 3.6% in the second quarter. Russell Investments Group Ltd. now owns 45,738 shares of the company’s stock worth $1,915,000 after purchasing an additional 1,578 shares during the last quarter. Hedge funds and other institutional investors own 96.77% of the company’s stock.
In other Catalent news, insider John R. Chiminski sold 130,545 shares of the stock in a transaction that occurred on Monday, October 1st. The stock was sold at an average price of $45.32, for a total value of $5,916,299.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Donald E. Morel, Jr. acquired 10,000 shares of the company’s stock in a transaction on Thursday, September 13th. The stock was acquired at an average price of $43.00 per share, with a total value of $430,000.00. The disclosure for this purchase can be found here. Insiders have sold a total of 184,335 shares of company stock worth $8,161,727 over the last quarter. Corporate insiders own 1.40% of the company’s stock.
Catalent (NYSE:CTLT) last announced its quarterly earnings data on Tuesday, November 6th. The company reported $0.28 EPS for the quarter, beating the consensus estimate of $0.24 by $0.04. The firm had revenue of $551.80 million for the quarter, compared to analyst estimates of $582.44 million. Catalent had a return on equity of 19.13% and a net margin of 2.65%. The company’s revenue was up 1.5% on a year-over-year basis. During the same period in the prior year, the company earned $0.21 EPS. As a group, research analysts anticipate that Catalent Inc will post 1.63 EPS for the current fiscal year.
A number of research analysts have recently commented on the company. Morgan Stanley set a $46.00 price target on Catalent and gave the company a “buy” rating in a research report on Monday. Royal Bank of Canada set a $45.00 price target on Catalent and gave the company a “buy” rating in a research report on Friday, November 16th. Robert W. Baird assumed coverage on Catalent in a research report on Thursday, November 15th. They set an “outperform” rating on the stock. Zacks Investment Research cut Catalent from a “hold” rating to a “sell” rating in a research report on Monday, November 12th. Finally, ValuEngine upgraded Catalent from a “hold” rating to a “buy” rating in a research note on Monday, November 12th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and ten have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $48.00.
COPYRIGHT VIOLATION NOTICE: This article was reported by Baseball Daily News and is owned by of Baseball Daily News. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this article can be accessed at https://www.baseballdailydigest.com/news/2018/12/03/aperio-group-llc-acquires-2185-shares-of-catalent-inc-ctlt.html.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Recommended Story: What are defining characteristics of a correction?
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.